[1] Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53(2):211-216. DOI:
10.1177/1060028018797110[2] Kim SH, et al. Efficacy and safety of radotinib in chronic phase chronic myeloid leukemia patients with resistance or intolerance to BCR-ABL1 tyrosine kinase inhibitors. Haematologica. 2014 Jul;99(7):1191-6. DOI:
10.3324/haematol.2013.096776[3] M S ZABRISKIE. Radotinib is an effective inhibitor of native and kinase domain-mutant BCR-ABL1[J]. Leukemia, 2015, 29 9: 1939-1942. DOI:
10.1038/leu.2015.42[4] SOOK-KYOUNG HEO. Radotinib Induces Apoptosis of CD11b+ Cells Differentiated from Acute Myeloid Leukemia Cells.[J]. PLoS ONE, 2015: e0129853. DOI:
10.1371/journal.pone.0129853
